Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Acta oncologica
| Acta oncologica |
| Pubbl/distr/stampa | [Oslo, Norway], : Scandinavian University Press |
| Descrizione fisica | 1 online resource |
| Disciplina | 614.59994 |
| Soggetto topico |
Oncology
Cancer - Treatment Medical radiology Physics Cancer Medical Oncology Neoplasms - therapy Radiation Effects Cancérologie Cancer - Traitement Physique physics Quimioteràpia del càncer Oncologia |
| Soggetto genere / forma |
Review
Periodicals. Periodical Revistes electròniques |
| ISSN | 1651-226X |
| Formato | Materiale a stampa  |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910142607103321 |
| [Oslo, Norway], : Scandinavian University Press | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Atlas of clinical PET-CT in treatment response evaluation in oncology / / Stefano Fanti, Gopinath Gnanasegaran, Ignasi Carrió, editors
| Atlas of clinical PET-CT in treatment response evaluation in oncology / / Stefano Fanti, Gopinath Gnanasegaran, Ignasi Carrió, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (483 pages) |
| Disciplina | 616.99407575 |
| Soggetto topico |
Cancer - Tomography
Quimioteràpia del càncer Radioteràpia Tomografia per emissió de positrons |
| Soggetto genere / forma |
Llibres electrònics
Atles (Científic) |
| ISBN | 3-030-68858-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- List of Contributors -- Part I: Therapy Response Evaluation: Science and Practice -- 1: Treatment Response Evaluation: Science and Practice -- 1.1 Introduction -- 1.2 Criteria for Evaluating Response -- 1.3 Traditional Response Criteria -- 1.4 Incorporation of Molecular Imaging into Response Criteria -- 1.5 Response Criteria and Immunotherapy -- 1.6 Practical Considerations -- References -- 2: CT in Treatment Response Assessment in Oncology -- 2.1 Introduction -- 2.2 Current Response Assessment Criteria for Chemotherapy and Targeted Therapies -- 2.3 Pitfalls of RECIST 1.1 -- 2.4 mRECIST in HCC -- 2.5 Lugano Classification in Lymphoma -- 2.6 Response Assessment Criteria in Immunotherapy -- 2.7 Conclusion -- References -- 3: MRI and Diffusion-Weighted MRI in Treatment Response Evaluation Overview -- 3.1 Introduction -- 3.2 Response Evaluation by Tumour Burden or Anatomical Parameters -- 3.2.1 WHO and RECIST Criteria -- 3.2.2 iRECIST -- 3.2.3 Other Response Evaluation by Anatomical MRI in Specific Disease Contexts -- 3.2.3.1 Brain Tumour -- 3.2.3.2 Hepatocellular Carcinoma (HCC) -- 3.2.3.3 Rectal Cancer -- 3.3 Response Evaluation with Diffusion-Weighted Imaging (DWI) -- 3.4 Conclusion -- References -- 4: PET and PET-CT in Treatment Response Evaluation: Overview -- 4.1 Introduction: Why Is Tumor Response Assessed by Imaging? -- 4.2 Assessment of Tumor Response: When and How? -- 4.2.1 Response Assessment by FDG PET -- 4.2.1.1 Response Assessment in Lymphoma -- 4.2.2 Response Assessment with Other PET Imaging Agents -- 4.2.3 Timing of Response Assessment -- 4.3 Responders vs. Nonresponders -- 4.4 Management and Type of Treatment -- 4.5 Common Patterns, Pitfalls, Variants, Advantages, and Limitations -- 4.5.1 Standardized Imaging Protocol -- 4.5.2 Impact of Therapy on FDG Metabolism.
4.5.3 Radiation Therapy -- 4.5.4 Immunotherapy -- 4.5.5 Clinical Image Interpretation -- References -- 5: Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Postsurgical Setting -- 5.1 Introduction -- 5.2 Computed Tomography (CT) -- 5.3 Magnetic Resonance Imaging (MRI) -- 5.4 Positron Emission Tomography (PET) -- 5.5 Other Radiotracers (Neuroendocrine Tumors, Prostate Cancer) -- 5.6 Conclusion -- References -- 6: Conventional Radiological and PET-CT Assessment of Treatment Response Evaluation in Chemotherapy Setting -- 6.1 Introduction -- 6.2 Conventional Radiological Techniques -- 6.3 PET/CT in Response Assessment to Chemotherapy -- 6.3.1 EORTC -- 6.3.2 IHP Criteria for Lymphoma -- 6.3.3 Deauville Criteria for Lymphoma -- 6.3.4 PERCIST -- 6.4 MRI and CT in Response Assessment to Chemotherapy -- 6.5 Evaluation of Response to Chemotherapy in Individual Tumours -- 6.5.1 Oesophageal and Gastric Cancer -- 6.5.2 Colorectal Cancer -- 6.5.3 Hepatocellular Carcinoma -- 6.5.4 Pancreatic Cancer -- 6.5.5 Lung Cancer -- 6.5.6 Lymphoma -- 6.5.7 Head and Neck Cancer -- 6.5.8 Breast Cancer -- 6.5.9 Other Tumours -- 6.6 Conclusion -- References -- 7: Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Post-Radiotherapy Setting -- 7.1 Introduction -- 7.2 Functional Imaging for Disease Response Assessment to Radiotherapy -- 7.2.1 Functional, Metabolic PET Imaging -- 7.2.1.1 Glucose Metabolism -- 7.2.1.2 Tumor Hypoxia -- 7.2.1.3 Tumor Cell Proliferation -- 7.2.1.4 Apoptosis -- 7.2.1.5 Amino Acid Transport and Protein Synthesis -- 7.2.1.6 Cell Membrane Synthesis -- 7.2.1.7 Epidermal Growth Factor Receptor Status -- 7.2.2 Functional MR Imaging Techniques -- 7.2.2.1 Dynamic Contrast-Enhanced MR Imaging -- 7.2.2.2 Diffusion-Weighted MR Imaging -- 7.2.2.3 BOLD Imaging. 7.2.2.4 MR Spectroscopy -- 7.2.3 Functional Imaging with Perfusion CT -- 7.2.4 Emerging Integrated Hybrid Imaging Techniques -- 7.2.4.1 Integrated PET/CT Perfusion Imaging -- 7.2.4.2 Integrated PET-MR Imaging -- 7.3 Assessment of Treatment Response After Radiotherapy -- 7.3.1 Anatomic Response Criteria (WHO, RECIST) -- 7.3.1.1 WHO Criteria -- 7.3.1.2 RECIST v1.1 -- 7.3.1.3 Limitations of Anatomic Response Criteria -- 7.3.2 Metabolic Response Criteria -- 7.3.2.1 Qualitative Assessment -- 7.3.2.2 Quantitative Assessment (PERCIST v1.0) -- 7.4 Current Uses of FDG PET/CT in Treatment Response Following Radiation Therapy -- 7.4.1 Head and Neck Cancer -- 7.4.2 Esophageal Carcinoma -- 7.4.3 Rectal Carcinoma -- 7.4.4 Brain Tumors -- 7.4.5 Cervical Carcinoma -- 7.4.6 Lung Carcinoma -- 7.4.7 Hepato-Pancreatico-Biliary Tumors, Particularly Pancreatic Carcinoma and Liver Metastases (Postselective Internal Radiotherapy Treatment) -- References -- 8: Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings -- 8.1 Introduction -- 8.2 Management: Type of Treatments/Regimes -- 8.2.1 Melanoma -- 8.2.2 NSCLC -- 8.2.3 Other Solid Tumors -- 8.3 Pathophysiology -- 8.4 Assessment of Treatment Response -- 8.4.1 Anatomic Response Assessment -- 8.4.2 Metabolic Response Criteria -- 8.4.3 Responders Vs. Non-Responders -- 8.4.4 Pitfalls and beyond (Pseudo-, Hyper-Progression, irAEs, Brain Mets, Cost-Effectiveness) -- References -- 9: Treatment Response Evaluation of Bone Metastases Using 18F-NaF -- 9.1 Introduction -- 9.2 Management and Types of Treatments -- 9.2.1 Baseline 18F-Fluoride PET/CT -- 9.2.1.1 Prostate Cancer -- 9.2.1.2 Breast Cancer -- 9.2.1.3 Lung Cancer -- 9.2.1.4 Thyroid Cancer -- 9.2.1.5 Renal Cell Cancer. 9.3 Assessment of Treatment Response (Postsurgical, Post Chemotherapy, Post Radiotherapy, Neoadjuvant, and Immunotherapy Settings) -- 9.3.1 Interim 18F-Fluoride PET/CT -- 9.3.1.1 Prostate Cancer -- 9.3.1.2 Breast Cancer -- 9.3.2 Follow-Up 18F-Fluoride PET/CT -- 9.3.2.1 Prostate Cancer -- 9.3.2.2 Breast Cancer -- 9.3.2.3 Multiple Myeloma -- 9.3.2.4 Metastatic Primary Bone Tumors -- 9.3.3 Conclusions -- 9.4 Common Patterns, Pitfalls, Variants, Advantages, and Limitations -- References -- 10: Reporting Post-Therapy Scans -- 10.1 Introduction -- 10.2 Patient Preparation -- 10.3 Clinical Details -- 10.4 Questions to Ask Patient -- 10.5 When to Scan -- 10.6 What to Look for in the Scans -- 10.7 How to Describe, Report Post-Therapy Finding Scores, Criteria, etc. (Post-Surgical, Post-Chemotherapy, Post-Radiotherapy, and Post-Immunotherapy Settings) -- 10.8 Common and Less Common Findings -- 10.9 How to Interpret the Findings: Dos and Don'ts -- 10.9.1 What to Do -- 10.9.2 What Not to Do -- 10.10 What to Advise the Referrers -- References -- Part II: Therapy Response Evaluation: Clinical Atlas -- 11: 18F-FDG PET/CT in Treatment Response Evaluation in Head and Neck Cancer -- 11.1 Case 1 -- 11.2 Case 2 -- 11.3 Case 3 -- 11.4 Case 4 -- 11.5 Case 5 -- 11.6 Case 6 -- 11.7 Case 7 -- 11.8 Case 8 -- 11.9 Case 9 -- 11.10 Case 10 -- 11.11 Case 11 -- 11.12 Case 12 -- 11.13 Case 13 -- 11.14 Case 14 -- 11.15 Case 15 -- Suggested Reading -- Case 3 -- 12: PET/CT in Treatment Response Evaluation: Lung Cancer -- 12.1 Introduction -- References -- 13: 18F-FDG PET/CT and Non 18F-FDG-PET/CT in Treatment Response Evaluation in Neuro-Oncology -- 13.1 Introduction -- 13.2 PET Tracers Used in Neuro-Oncology -- 13.3 Case 1 -- 13.4 Case 2 -- 13.5 Case 3 -- 13.6 Case 4 -- 13.7 Case 5 -- 13.8 Case 6 -- 13.9 Case 7 -- 13.10 Case 8. 13.11 Case 9 -- 13.12 Case 10 -- 13.13 Case 11 -- 13.14 Case 12 -- 13.15 Case 13 -- 13.16 Case 14 -- 13.17 Case 15 -- References -- 14: PET/CT in the Assessment of Treatment Response in Hepatobiliary, Gall Bladder and Pancreatic Malignancies -- 14.1 Introduction -- 14.2 Case 1 -- 14.3 Case 2 -- 14.4 Case 3 -- 14.5 Case 4 -- 14.6 Case 5 -- 14.7 Case 6 -- 14.8 Case 7 -- 14.9 Case 8 -- 14.10 Case 9 -- 14.11 Case 10 -- 14.12 Case 11 -- 14.13 Case 12 -- 14.14 Case 13 -- 14.15 Case 14 -- 14.16 Case 15 -- 14.17 Case 16 -- 14.18 Case 17 -- 14.19 Case 18 -- Suggested Reading -- Introduction -- Case 1 -- Case 2 -- Case 3 -- Case 4 -- Case 6 -- Case 7 -- Case 8 -- Case 11 -- 15: 18F-FDG PET/CT in Treatment Response Evaluation: Gastroesophageal Cancer -- 15.1 Introduction -- 15.2 Case No. 1: Radiation-Induced Esophagitis -- 15.3 Case No. 2: Radiation-Induced Pneumonitis -- 15.4 Case No. 3: Post Transthoracic Esophagectomy (TTE) Appearance -- 15.5 Case No. 4: Aspiration Pneumonia -- 15.6 Case No. 5: Recurrent Aspiration Pneumonia -- 15.7 Case No. 6: Tracheoesophageal Fistula (TOF) -- 15.8 Case No. 7: Upper Esophageal Mass with Complete Response Post CTRT -- 15.9 Case No. 8: Post CTRT Complete Response with Inflammatory Changes in the Esophagus -- 15.10 Case No. 9: Complete Response on PET/CT with Microscopic Residual Disease on Histopathology -- 15.11 Case No. 10: Posttreatment Changes Vs. Residual Disease -- 15.12 Case No. 11: Partial Response to Treatment -- 15.13 Case No. 12: Stable Disease with Radiation-Induced Esophagitis -- 15.14 Case No. 13: GE Junction Mass with Partial Response -- 15.15 Case No. 14: Complete Response -- 15.16 Case No. 15: Coexisting Malignancy and Granulomatous Infection -- 15.17 Case No. 16: Esophageal Primary with Coexisting Tuberculous Infection in the Lungs. 15.18 Case No. 17: GE Junction and Proximal Stomach Mass with Partial Response. |
| Record Nr. | UNINA-9910491028203321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Dermato-oncology study guide : essential text and review / / Vincent Liu, Editor
| Dermato-oncology study guide : essential text and review / / Vincent Liu, Editor |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (394 pages) : illustrations |
| Disciplina | 616.99477 |
| Soggetto topico |
Chemotherapy
Oncology Dermatology Dermatologia Oncologia Quimioteràpia del càncer |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-53437-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910484092603321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer : new understandings and therapies / / Anne C. Chiang, Roy S. Herbst, editors
| Lung cancer : new understandings and therapies / / Anne C. Chiang, Roy S. Herbst, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Humana, , [2021] |
| Descrizione fisica | 1 online resource (263 pages) |
| Disciplina | 616.99424 |
| Collana | Current cancer research |
| Soggetto topico |
Lungs - Cancer
Lung Neoplasms - therapy Càncer de pulmó Quimioteràpia del càncer Radioteràpia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-74028-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- Chapter 1: Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- 1 Introduction -- 2 The Tumor Compartment -- 2.1 Immune Inhibitory Signals -- 2.2 Immune Suppressive Cytokines -- 2.3 Antigen Presentation Machinery Alterations -- 2.4 Altered Intracellular Signaling and Differentiation -- 3 The Stromal Compartment -- 3.1 Immune Cells in the Stroma -- 3.1.1 Adaptive Immune Cells: T Lymphocytes -- 3.1.2 Adaptive Immune Cells: B Lymphocytes -- 3.1.3 Innate Immune Cells: NK Cells -- 3.1.4 Innate Immune Cells: Myeloid Cells -- 3.2 Non-immune Cells in the Stroma -- 3.2.1 Non-immune Cells in the Stroma: Cancer Associated Fibroblasts (CAFs) -- 3.2.2 Non-immune Cells in the Stroma: Vascular Cells -- 3.3 Non-Cellular Elements of the TME: The Extracellular Matrix (ECM) -- 4 Biomarkers -- 4.1 Validated Biomarkers in the Tumor -- 4.1.1 PD-L1 Expression -- 4.1.2 Oncogenic Drivers -- 4.1.3 Tumor Mutational Burden -- 4.2 Validated Biomarkers in the Stroma -- 4.2.1 Tumor Infiltrating Lymphocytes (TILs) -- 4.2.2 T-Cell RNA Signatures -- 4.2.3 Developing Biomarkers -- Interferon Gamma Response Pathway -- Beta-2-Microglobulin Alterations -- DNA Sensing Alterations: LKB1 -- FBXW7 -- TGFß Pathway -- Activation of Alternative Immune Pathways -- Microbiome -- Immune Heterogeneity -- 5 Conclusions -- References -- Chapter 2: Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail? -- 1 Introduction -- 2 Definition of TMB and TMB Assessment Methods -- 3 TMB and Association with Response to ICIs -- 3.1 Pembrolizumab -- 3.2 Nivolumab -- 3.3 Atezolizumab -- 3.4 Durvalumab, Durvalumab Plus Tremelimumab -- 3.5 Nivolumab Plus Ipilimumab -- 3.6 Real-World Analyses -- 4 Efficacy of TMB as a Predictive Biomarker -- 5 Pragmatic Limitations -- 5.1 TMB Standardization -- 5.2 Feasibility of Assessing TMB in Routine Clinical Practice.
6 Biology Underlying the Response Association -- 7 Integrating TMB with Other Biomarkers of ICI Response -- 8 Conclusion -- References -- Chapter 3: Liquid Biopsies: New Technology and Evidence -- 1 Introduction -- 2 Circulating Tumor DNA -- 3 Initial Molecular Profiling in NSCLC -- 4 Detection of the Mechanism of Acquired Resistant to Targeted Therapy -- 5 Detection of Minimal Residual Disease -- 6 Small Cell Lung Cancer -- 7 Extracellular Vesicles -- 8 Circulating Tumor Cells -- 9 Conclusion -- References -- Chapter 4: Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- 1 Clinical Activity of Osimertinib -- 2 Activity in CNS and Leptomeningeal Disease -- 3 Osimertinib in the Adjuvant Setting -- 4 Resistance to Osimertinib -- 5 Conclusion -- References -- Chapter 5: Immune Therapy: What Can We Learn From Acquired Resistance? -- 1 Introduction -- 2 Defining Acquired Resistance -- 2.1 Classification Based on Initial Response -- 2.2 Acquired Resistance Versus Off-Therapy Progression -- 3 Clinical Observations in Patients with Advanced NSCLC and Acquired Resistance to PD-1 Axis Inhibitors -- 4 Concepts in the Management of Acquired Resistance to PD-1 Axis Inhibitors in Advanced NSCLC -- 4.1 Local Therapy -- 4.2 Resume/Re-Challenge with PD-1 Axis Inhibitor Therapy -- 4.3 PD-1 Axis Inhibitor Combinations -- 4.3.1 PD-1 Axis Inhibitors + CTLA-4 Inhibitors -- 4.3.2 Novel Combination Strategies for PD-1 Axis Inhibitor Relapsed/Refractory NSCLC -- PD-1 Axis Inhibitor + Interleukin Receptor Agonist -- PD-1 Axis Inhibitor + Histone Deacetylase Inhibitors (HDACi) -- PD-1 Axis Inhibitor + Adenosine A2A Receptor Antagonists -- PD-1 Axis Inhibitor + Sitravatinib -- PD-1 Axis Inhibitor + Anti-TIM-3 -- Retinoic Acid Receptor-Related Orphan Receptor γ (RORγ) +/− PD-1 Axis Inhibitor. 4.4 Chemotherapy Sensitization -- 5 Mechanisms Mediating Acquired Resistance to PD-1 Axis Inhibitors in NSCLC -- 5.1 Acquired Neoantigen Loss -- 5.2 Acquired Antigen Processing and Presentation Defects -- 6 Uncovering Mechanisms of IO-Acquired Resistance in Other Tumor Types -- 6.1 Acquired Defects in Interferon-Gamma (IFN- γ) Signaling and Antigen Presentation -- 6.2 Immune-Suppressive Changes in the Tumor Microenvironment -- 6.3 PTEN Loss -- 6.4 Novel Experimental Discoveries -- 6.5 Conclusions and Future Visions -- References -- Chapter 6: Management of Brain Metastases -- 1 Introduction -- 2 Local Treatments for Brain Metastases: The Historical Standard of Care -- 3 Challenges in the Use of Systemic Treatment for Brain Metastases -- 4 Systemic Therapies for Brain Metastases in NSCLC -- 4.1 Chemotherapy -- 4.2 Targeted Therapies -- 4.2.1 EGFR Mutations -- 4.2.2 ALK Rearrangements -- 4.2.3 Other Driver Mutations (ROS1, RET, BRAF, MET, NTRK) -- 4.3 Immunotherapy - Checkpoint Inhibitors -- 5 Conclusions -- References -- Chapter 7: Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- 1 Introduction -- 1.1 Clinical Scenario -- 1.2 Mechanism of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- 1.3 Incidence of IRAEs by Agent and in Combination -- 1.4 Biomarkers to Identify Patients at Risk for Developing IRAEs -- 2 Management of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors (ICPIs) -- 3 Organ Specific Immune-Related Adverse Events -- 3.1 Dermatologic -- 3.2 Gastrointestinal -- 3.3 Pulmonary -- 3.4 Endocrine -- 3.5 Hepatic -- 3.6 Renal -- 3.7 Cardiac -- 3.8 Neurologic -- 3.9 Musculoskeletal-Rheumatologic -- 3.10 Ocular -- 3.11 Hematologic -- 4 Summary -- References -- Chapter 8: Therapeutic Advances in Small Cell Lung Cancer Management -- 1 Introduction. 2 Limited Stage Small Cell Lung Cancer -- 2.1 Surgery for Limited Stage Small Cell Lung Cancer -- 2.2 Chemoradiation for Limited Stage Small Cell Lung Cancer -- 2.3 Checkpoint Inhibitors in Limited Stage Small Cell Lung Cancer -- 2.4 Prophylactic Cranial Radiation for Limited Stage Small Cell Lung Cancer -- 2.5 Surveillance After Initial Management of Limited Stage Small Cell Lung Cancer -- 3 Extensive Stage Small Cell Lung Cancer -- 3.1 Thoracic Irradiation as Consolidation Therapy -- 3.2 Prophylactic Cranial Radiation in Extensive Stage Small Cell Lung Cancer -- 4 Brain Metastasis -- 5 Treatment of Refractory and Relapsed Small Cell Lung Cancer -- 5.1 Checkpoint Inhibitor Therapy for Relapsed Disease -- 5.2 Chemotherapy for Relapsed Disease -- 5.3 Beyond the Second Line -- 6 Novel Treatments -- 6.1 DNA Repair -- 6.2 MYC Gene Family -- 6.3 Epigenetics -- 6.4 Other Approaches -- 7 Conclusion -- References -- Chapter 9: Small Cell Lung Cancer: Biology Advances -- 1 Introduction -- 2 Identifying Therapeutic Targets in SCLC -- 2.1 DNA Damage Response (DDR) Proteins -- 2.2 DDR Inhibition and Immunotherapy -- 2.3 MYC -- 2.4 Targets in Developmental Pathways -- 2.5 BCL2 -- 2.6 Epigenetic Inhibitors -- 3 Immunotherapy: Recent Approvals, Biomarkers and Novel Combinations -- 4 A New Classification System: SCLC Subtypes Based on Dominant Gene Expression Profile -- 5 Conclusions -- References -- Chapter 10: Immunotherapy and Radiotherapy: New Strategies -- 1 Introduction -- 2 Radiotherapy as In Situ Vaccine -- 2.1 Principles of Vaccination as Applied to NSCLC -- 2.2 Radiotherapy as Both Antigen and Adjuvant -- 3 Radiotherapy and the Innate Immune System -- 3.1 Immunogenic Cell Death -- 3.2 DNA Damage Machinery and Pattern Recognition Receptors: An Emerging Overlap -- 3.3 Recognition of DNA Damage with cGAS/STING -- 3.4 Recognition of DNA Damage with AIM2. 3.5 RAD51 at the Intersection of the DNA Damage Response and Innate Immunity -- 3.6 Radiotherapy and RNA Sensing: RIG-I -- 3.7 Type I IFN in Acute and Chronic Settings -- 3.8 Immunostimulatory Effects of Acute Type I IFN in Cancer -- 3.9 Immunosuppressive Effects of Chronic Type I IFN in Cancer -- 4 Radiotherapy and the Adaptive Immune System -- 4.1 Priming of the Adaptive Immune System -- 4.2 The Importance of Cross-Presentation in the Anti-tumoral Response -- 4.3 Radiotherapy and Immunological Memory -- 4.4 T Cell Exhaustion within the Tumor Microenvironment -- 4.5 Checkpoint Inhibition and Radiotherapy -- 5 Maximizing the Clinical Utility of Radiotherapy in an Era of Checkpoint Inhibition: New Strategies -- 5.1 Rational Treatment Design -- 5.2 Choice of Target -- 5.3 Timing -- 5.4 Dose and Fractionation -- 6 Conclusions -- References -- Chapter 11: Ultimate Precision: Targeting Cancer But Not Normal Self-Replication -- 1 Introduction -- 2 Replication and Lineage-Differentiation Are Linked -- 3 Dis-Engaging Replication from Advances Along a Lineage -- 4 The Importance of Reconciling These Different Models -- 5 Cell-of-Origin Versus Cell-of-Transformation -- 6 Master Transcription Factor Alterations in Cancer Cells -- 7 Targeting Cancer, But Not Normal, Self-Replication -- 8 Conclusion -- References -- Index. |
| Record Nr. | UNINA-9910502622503321 |
| Cham, Switzerland : , : Humana, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Quimioteràpia del càncer
(4)
- Oncologia (2)
- Oncology (2)
- Radioteràpia (2)
- Cancer (1)